key: cord-0759038-kpwzks75
authors: Sun, Yuwei; Miller, D. Claire; Akpandak, Idara; Chen, Evan M.; Arnold, Benjamin F.; Acharya, Nisha R.
title: Association between immunosuppressive drugs and COVID-19 outcomes in patients with non-infectious uveitis in a large US claims database
date: 2022-05-17
journal: Ophthalmology
DOI: 10.1016/j.ophtha.2022.05.008
sha: 0b5a2d02491a7099301554d020d16df3689ffe85
doc_id: 759038
cord_uid: kpwzks75

PURPOSE: To determine the dose-dependent risk of systemic corticosteroids and the risk of other immunosuppressive therapies on coronavirus 2019 (COVID-19) infection, hospitalization, and death in patients with non-infectious uveitis (NIU). DESIGN: A retrospective cohort study from January 20, 2020 to December 31, 2020 (an era before widespread COVID-19 vaccination) using the Optum Labs Data Warehouse, a U.S. national de-identified claims database. PARTICIPANTS: Patients who had at least one NIU diagnosis from January 1, 2017. METHODS: Unadjusted and adjusted hazard ratios were estimated for each variable and COVID-19 outcome using Cox proportional hazards models, with time-updated dichotomous indicators for outpatient immunosuppressive medication exposure. To assess the dose-dependent effect of systemic corticosteroid exposure, the average daily dose of prednisone over the exposed interval was included in the adjusted models as a continuous variable, in addition to the dichotomous variable. MAIN OUTCOME MEASURES: Incidence rates of COVID-19 infection, COVID-19-related hospitalization, and COVID-19-related in-hospital death. RESULTS: This study included 52 286 NIU patients of whom 12 000 (23.0%) were exposed to immunosuppressive medications during the risk period. In adjusted models, exposure to systemic corticosteroids was associated with increased risk of COVID-19 infection (hazard ratio [HR] = 2.66; 95% confidence interval [CI]: 2.19 – 3.24; p < 0.001), hospitalization (HR = 3.26; 95% CI: 2.46 – 4.33; p < 0.001), and in-hospital death (HR = 1.99; 95% CI: 0.93 – 4.27; p = 0.08). Furthermore, incremental increases in the dosage of systemic corticosteroids were associated with a greater risk for these outcomes. While tumor necrosis factor alpha (TNF-α) inhibitors were associated with an increased risk of infection (HR = 1.48; 95% CI: 1.08 – 2.04; p = 0.02), other immunosuppressive treatments did not increase the risk of COVID-19 infection, hospitalization or death. CONCLUSIONS: This study from an era before widespread COVID-19 vaccination demonstrates that outpatient systemic corticosteroid exposure is associated with greater risk of COVID-19 infection and severe outcomes in patients with NIU. Future studies should evaluate the impact of immunosuppression in vaccinated NIU patients. Limiting exposure to systemic corticosteroids and use of alternative therapies may be warranted.

Time-varying dichotomous exposure to each category of immunosuppressive medication was characterized based on dispensing information available in outpatient pharmacy claims. Patients 151 were considered exposed to an immunosuppressive medication from the day the prescription was "days' supply" variable provided within the pharmacy claim, which was recorded by the pharmacist as an estimate of the number of days that a prescription was expected to last if the prescription 155 instructions were followed. Supplemental Methods 1 describes how gaps and overlaps between 156 subsequent prescription fills were handled. 25, 26 calculated using the formula ℎ × ′ . For example, if a prednisone 160 prescription fill had a 7 days supply, quantity drug unit of 21 pills, and drug strength of 10 mg per 161 each unit, the average daily dose of this prednisone fill would be 10 mg * 21/7 days = 30 mg/day.

The tapering regimen of SC was not available from pharmacy claims. three or more fills.

exposed to SC compared to 39.9 cases per 1000 person-years in the SC unexposed group, corresponding to an incidence rate ratio of 2.88 (Table 3 ). The incidence rate was slightly higher 257 in the exposed person-time for DMARDs, TNF- inhibitors, other biologics, and other 258 immunosuppressive drugs ( 

Exposures associated with COVID-19-related hospitalization

The incidence rate of COVID-19-related hospitalization was 56.7 cases per 1 000 person-years 272 in patients exposed to SC compared to 13.5 cases per 1 000 person-years in the SC unexposed 273 group, corresponding to an incidence rate ratio of 4.20 (Table 3 ). The unadjusted hazard ratio for (95% CI: 3.31 -5.48; p<0.001) (Table 4) .

In the adjusted analysis, SC exposure tripled the hazard of hospitalization (HR = 3.26; 95% CI: (Table 4 ).

After covariate adjustment, the point estimates suggested an increased risk for all the exposure 284 levels of corticosteroids in the secondary analysis ( Figure 2 ), although the confidence intervals 285 for short-term <= 10 mg/day, short-term > 10 and <= 20 mg/day crossed 1. In our NIU cohort, 72 286 (0.14%) patients were exposed to short-term <= 5 mg/day prednisone and less than 11 of them 287 were hospitalized with COVID-19. The adjusted hazard ratio was 2.65 (95% CI: 0.66 -10.64; p = 288 0.17). Three hundred twenty-one (0.61%) patients were exposed to long-term <= 5 mg/day 289 prednisone, with an adjusted hazard ratio for COVID-19 hospitalization of 1.98 (95% CI: 1.01 -290 3.87; p = 0.05).

Exposures associated with COVID-19-related in-hospital death

The incidence rate of COVID-19 related death in an inpatient facility was 7.3 cases per 1 000 294 person-years in the SC exposed group compared to 2.7 cases per 1 000 person-years in the SC 295 unexposed group, corresponding to an incidence rate ratio of 2.70 ( There were 11 520 (22% of the entire NIU cohort) patients under age 50, 1 743 (15.1%) of whom 314 were exposed to SC. There were 40 762 patients aged 50 and older, 7 773 (19.1%) of whom 315 were exposed to SC. In the adjusted analysis, risk of SC exposure on COVID-19 infection and 316 hospitalization was comparable between the older and younger age groups (Supplemental Table   317 6). There were no COVID-19 in-hospital deaths in patients exposed to SC in the subgroup under 318 age 50. The association between SC exposure and COVID-19 hospitalization remained in the 319 subgroups without asthma, without other autoimmune diseases and without chronic lung diseases 320 (Supplemental Table 7 per individual). Insurance information is usually asked in mass COVID-19 testing site but it's not are more dependent on severity of illness rather than access to the healthcare system. Lastly, we

were not able to analyze some specific drug classes separately due to limited sample size in 459 these subgroups. 

Female Male Unknown Table 2 . Immunosuppressive drug prescriptions during the risk period a (N=52,286) NIU=non-infectious uveitis; DMARDs=disease-modifying anti-rheumatic drugs; TNF-alpha=tumor necrosis factor alpha; IL-6=interleukin 6. a Frequencies and percentages reflect the proportion of patients who filled one or more prescriptions during risk period up to COVID-19 hospitalization outcome date (results differ slightly for infection and death outcomes).

Anakinra for severe forms of COVID-19: a cohort 42

4%) 115 (0.2%) Insurance type Commercial Medicare Advantage

Systemic corticosteroid exposure is associated with greater risk of COVID-19 infection, hospitalization, and death in patients with non-infectious uveitis

J o u r n a l P r e -p r o o f 

Overall: 118 cases within 42,018 person years, corresponding to an incidence rate of 3 per 1000 person-years J o u r n a l P r e -p r o o f DMARDs=disease-modifying anti-rheumatic drugs; TNF-alpha=tumor necrosis factor alpha; IL-6=interleukin 6. a To protect patient privacy, OptumLabs doesn't allow to report the true value of a count if it is less than 11. Only incidence rate was reported because the number of cases in the category is less than 11. The corresponding person-years are also not reported to prevent back calculation. a P-values calculated from Cox proportional hazards models. b We were not able to estimate the hazard ratio and corresponding p-value due to zero outcome event in the exposed group. The journal adheres to the Uniform Requirements set by the International Committee of Medical Journal Editors (http://www.icmje.org/) for authorship. To qualify for authorship, authors must make substantial contributions to the intellectual content of the paper in each of the four following categories:1. Substantial contributions to conception and design of the work; or the acquisition, analysis, or interpretation of data for the work; AND 2. Drafting the work or revising it critically for important intellectual content; AND 3. Final approval of the version to be published; AND 4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.It is the responsibility of the corresponding author, prior to submitting the manuscript, to confirm that each coauthor meets the requirements for authorship. Please list all authors of the manuscript on the Contributorship Statement form below. The form need not be uploaded at the time of original manuscript submission but rather if/when the Editorial Board invites revision.By submitting this form, the corresponding author acknowledges that each author has read the statement on authorship responsibility and contribution to authorship. In the table below, please designate the contributions of each author. Any relevant contribution not described in the four columns can be added under "Other contributions." Please note that the list of contributions will publish with the manuscript should it be accepted. Thank you. J o u r n a l P r e -p r o o f